(FLUO) Fluoguide AS - Ratings and Ratios
Exchange: ST • Country: Denmark • Currency: SEK • Type: Common Stock • ISIN: DK0061123312
FLUO: Cancer Drugs, Fluorescent Agents, Surgical Tools, Glioma Treatments, Lung Cancer
FluoGuide A/S, a clinical stage biotechnology company, focused on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. It has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; collaboration with Copenhagen University Hospital; collaboration with Intuitive Surgical, Inc. for robotics surgery in head and neck cancer. FluoGuide A/S was incorporated in 2018 and is headquartered in Copenhagen, Denmark. Web URL: https://fluoguide.com
Additional Sources for FLUO Stock
FLUO Stock Overview
| Market Cap in USD | 63m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception |
FLUO Stock Ratings
| Growth 5y | 20.2% |
| Fundamental | - |
| Dividend | - |
| Rel. Strength Industry | -767 |
| Analysts | - |
| Fair Price Momentum | 45.15 SEK |
| Fair Price DCF | - |
FLUO Dividends
No Dividends PaidFLUO Growth Ratios
| Growth Correlation 3m | 58.9% |
| Growth Correlation 12m | -78.4% |
| Growth Correlation 5y | -21.8% |
| CAGR 5y | 43.44% |
| CAGR/Mean DD 5y | 0.85 |
| Sharpe Ratio 12m | -0.29 |
| Alpha | -39.32 |
| Beta | 0.44 |
| Volatility | 64.08% |
| Current Volume | 3.5k |
| Average Volume 20d | 13.6k |
What is the price of FLUO stocks?
As of January 22, 2025, the stock is trading at SEK 50.00 with a total of 3,499 shares traded.
Over the past week, the price has changed by +11.98%, over one month by +40.85%, over three months by +27.39% and over the past year by -22.36%.
As of January 22, 2025, the stock is trading at SEK 50.00 with a total of 3,499 shares traded.
Over the past week, the price has changed by +11.98%, over one month by +40.85%, over three months by +27.39% and over the past year by -22.36%.
Is Fluoguide AS a good stock to buy?
Neither. Based on ValueRay Analyses, Fluoguide AS is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 20.17 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FLUO as of January 2025 is 45.15. This means that FLUO is currently overvalued and has a potential downside of -9.7%.
Neither. Based on ValueRay Analyses, Fluoguide AS is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 20.17 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FLUO as of January 2025 is 45.15. This means that FLUO is currently overvalued and has a potential downside of -9.7%.
Is FLUO a buy, sell or hold?
Fluoguide AS has no consensus analysts rating.
Fluoguide AS has no consensus analysts rating.
What are the forecast for FLUO stock price target?
According to ValueRays Forecast Model, FLUO Fluoguide AS will be worth about 49.3 in January 2026. The stock is currently trading at 50.00. This means that the stock has a potential downside of -1.46%.
According to ValueRays Forecast Model, FLUO Fluoguide AS will be worth about 49.3 in January 2026. The stock is currently trading at 50.00. This means that the stock has a potential downside of -1.46%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 135.1 | 170.1% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 49.3 | -1.5% |